InvestorsHub Logo

MontanaState83

04/02/20 1:53 PM

#260485 RE: biowreck #260476

If I may. Yes, the litigation is only about the Marine indication. But, the whole problem is doctors will prescribe the generic for the CV indication. It's F'd up.

NickHous

04/02/20 1:57 PM

#260489 RE: biowreck #260476

I know biowreck, if this so called just for Trigs >500 label is what the generics potentially gained (it will be appealed and injunction IMO, only thing to do) if they ever do gain entry for this early, how can it be explained that sales for Trigs >500 sales is so high and AMRNS Vascepa for CVD Red-It indication is so low. How can that be explained? Just a wink-wink by doctors and pharmacists and insurance companies all going along as recurring "just 12 week prescriptions" over and over to combat that pesky high Trigs>500. Bullshit, they are using it for the Red-It results. It is just so illogical. This was a hatchet job to steal ALL of Red-It label via back door illogical "obvious" ruling on an inferior BS nutritional trial. Seems FDA logic (I mean the FDA finally agreed on it, and were actually defending AMRN at the last adcom) and all the professional organizations thoughts and publications were ignored for a podunk circumspect "trial" (how can reliance be even put on that MORI trial. Be like "well I read a Meta-Analysis trial and it said......) This has to be overturned. People have been ignorant on EPA for years and apparently Judge's are no different. Unqualified judge ruled on this with unqualified data. ALL JMO.